Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia

被引：0

作者：

Enriqueta Albizua

Miguel Gallardo

Santiago Barrio

Inmaculada Rapado

Ana Jimenez

Rosa Ayala

Daniel Rueda

Beatriz Sanchez-Espiridion

Eulalia Puigdecanet

Blanca Espinet

Lourdes Florensa

Carles Besses

Joaquin Martinez-Lopez

机构：

[1] Hospital Universitario 12 de Octubre,Servicio de Hematología

[2] Servicio de Hematología,Laboratoris de Citologia Hematológica/Citogenética Molecular. Servei de Patologia, GRETNHE

[3] Hospital Virgen de la Salud,Servicio de Hematología

[4] Spanish National Cancer Research Centre (CNIO),undefined

[5] IMIM-Hospital del Mar,undefined

[6] IMIM-Hospital del Mar,undefined

来源：

Annals of Hematology | 2011年 / 90卷

关键词：

Polycythemia vera; Essential thrombocythemia; Gene expression profile; RT-PCR; Response to hydroxyurea; Src family kinase (SFK);

D O I：

暂无

中图分类号：

学科分类号：

摘要：

This study investigates the differential gene expression profile of JAK2V617F-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2V617F-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.

引用

页码：939 / 946

页数：7

共 50 条

[31] INFLUENCE OF ALLELIC LOAD OF JAK2V617F OF THE CD34+CELLS IN THE MOLECULAR RESPONSE TO THE TREATMENT WITH HYDROXYUREA IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA
Angona Figueras, A.
Alvarez Larran, A.
Bellosillo Paricio, B.
Longaron Rozalen, R.
Camacho Diaz, L.
Fernandez Rodriguez, C.
Pairet Garcia, S.
Garcia Pallarols, F.
Senin Megan, A.
Johansson Barron, E.
Torres Grande, E.
Besses Raebel, C.
HAEMATOLOGICA, 2015, 100 : 189 - 189
[32] Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
Yacoub, Abdulraheem
Mascarenhas, John
Kosiorek, Heidi
Prchal, Josef T.
Berenzon, Dmitry
Baer, Maria R.
Ritchie, Ellen
Silver, Richard T.
Kessler, Craig
Winton, Elliott
Finazzi, Maria Chiara
Rambaldi, Alessandro
Vannucchi, Alessandro M.
Leibowitz, David
Rondelli, Damiano
Arcasoy, Murat O.
Catchatourian, Rosalind
Vadakara, Joseph
Rosti, Vittorio
Hexner, Elizabeth
Kremyanskaya, Marina
Sandy, Lonette
Tripodi, Joseph
Najfeld, Vesna
Farnoud, Noushin
Papaemmanuil, Elli
Salama, Mohamed
Singer-Weinberg, Rona
Rampal, Raajit
Goldberg, Judith D.
Barbui, Tiziano
Mesa, Ruben
Dueck, Amylou C.
Hoffman, Ronald
BLOOD, 2019, 134 (18) : 1498 - 1509
[33] Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia
Vannucchi, Alessandro M.
Antonioli, Elisabetta
Guglielmelli, Paola
Rambaldi, Alessandro
Barosi, Giovanni
Marchioli, Roberto
Marfisi, Rosa Maria
Finazzi, Guido
Guerini, Vittoria
Fabris, Fabrizio
Randi, Maria Luigia
De Stefano, Valerio
Caberlon, Sabrina
Tafuri, Agostino
Ruggeri, Marco
Specchia, Giorgina
Liso, Vincenzo
Rossi, Edoardo
Pogliani, Enrico
Gugliotta, Luigi
Bosi, Alberto
Barbui, Tiziano
BLOOD, 2007, 110 (03) : 840 - 846
[34] IMPORTANCE OF JAK2 V617F ALLELE BURDEN IN THE DIAGNOSIS AND PHENOTYPIC MANIFESTATIONS OF ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
Sanchez Diego, Martin
Serna Raquel, Mata
Gonzalez Daniel, Lainez
Lopez Carlos, Blas
Bonilla Tamara, Castano
Sillero Pilar, Llamas
Juan Manuel, Alonso Dominguez
HAEMATOLOGICA, 2021, 106 (10) : 258 - 258
[35] Observation of a higher JAK2 V617F homozygous mutated clone in polycythemia vera compared to essential thrombocythemia
Liu H.
Tong C.
Cai P.
Gu J.
Lin Y.
Zhang Y.
Teng W.
Wang H.
Zhu P.
Frontiers of Medicine in China, 2008, 2 (3): : 309 - 313
[36] HYDROXYUREA DOSING VARIATIONS IN 82 PATIENTS WITH LONG-TERM TREATMENT OF ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA
Jose Maria, Guerra Hernando
Ivonne Lizett, Astudillo Romero
Salas Neus, Amer
Riera Martin, Mascaro
Lleonart Juan, Bargay
Garcia Raquel, Del Campo
Rodriguez Irene, Vazquez
Serra Antonia, Cladera
Perez Delia, Gomez
Bachs Elena, Gonzlez
Balanzat Ines, Herraez
HAEMATOLOGICA, 2021, 106 (10) : 257 - 258
[37] Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status
Finazzi, Guido
Rambaldi, Alessandro
Guerini, Vittoria
Carobbo, Alessandra
Barbui, Tiziano
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (01): : 135 - 136
[38] JAK2 (V617F)-Positive Essential Thrombocythemia and Polycythemia Vera Are Different Expressions Of a Genotypic/Phenotypic Continuum
Rumi, Elisa
Pietra, Daniela
Elena, Chiara
Casetti, Ilaria
Antonio, Emanuela Sant
Astori, Cesare
Milanesi, Chiara
Bellini, Marta
Boveri, Emanuela
Ferretti, Virginia
Pascutto, Cristiana
Cazzola, Mario
BLOOD, 2013, 122 (21)
[39] Limited effects on JAK2 mutational status after pegylated interferon α-2b therapy in polycythemia vera and essential thrombocythemia
Samuelsson, Jan
Mutschler, Manuel
Birgegard, Gunnar
Gram-Hansen, Poul
Bjorkholm, Magnus
Pahl, Heike L.
HAEMATOLOGICA, 2006, 91 (09) : 1281 - 1282
[40] JAK2 V617F allele burden and hemostatic profile of essential thrombocythemia (ET) and polycythemia vera (PV) patients
Marchetti, M.
Castoldi, E.
Russo, L.
Vignoli, A.
Rosing, J.
ten Cate, H.
Falanga, A.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 795 - 796

← 1 2 3 4 5 →